Immunotherapy Safety for the Primary Care ... - U.S. Coast Guard

J ALLERGY CLIN IMMUNOL
VOLUME 120, NUMBER 3
Cox et al S71
167. Purello-D’Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of
new sensitizations in monosensitized subjects submitted to specific immunotherapy
or not. A retrospective study. Clin Exp Allergy 2001;31:
1295-302.
168. Sampson HA. Food anaphylaxis. Br Med Bull 2000;56:925-35.
169. Rance F. [Current childhood food allergies]. Allerg Immunol (Paris)
2000;32:366-76. IIb
170. Bannon GA, Cockrell G, Connaughton C, et al. Engineering, characterization
and in vitro efficacy of the major peanut allergens for
use in immunotherapy. Int Arch Allergy Immunol 2001;124:70-2.
LB
171. Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic
sensitivity to peanuts by immunotherapy with injections of aqueous
peanut extract. J Allergy Clin Immunol 1997;99:744-51. IIa
172. Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut
food allergy: a randomized, double-blind, placebo-controlled
study with a standardized hazelnut extract. J Allergy Clin Immunol
2005;116:1073-9. Ib
173. Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY.
Treatment of peanut allergy with rush immunotherapy. J Allergy Clin
Immunol 1992;90:256-62. Ib
174. Werfel T, Breuer K, Rueff F, et al. Usefulness of specific immunotherapy
in patients with atopic dermatitis and allergic sensitization to house
dust mites: a multi-centre, randomized, dose-response study. Allergy
2006;61:202-5. Ib
175. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization
to Dermatophagoides pteronyssinus in children with atopic
eczema. Clin Exp Allergy 1992;22:440-6. Ib
176. Bussmann C, Böckenhoff A, Henke H, Werfel T, Novak N. Does
allergen-specific immunotherapy represent a therapeutic option for
patients with atopic dermatitis? J Allergy Clin Immunol 2006;118:
1292-8.
177. Bucher X, Pichler WJ, Dahinden CA, Helbling A. Effect of tree pollen
specific, subcutaneous immunotherapy on the oral allergy syndrome to
apple and hazelnut. Allergy 2004;59:1272-6. IIa
178. Hansen KS, Khinchi MS, Skov PS, Bindslev-Jensen C, Poulsen LK,
Malling HJ. Food allergy to apple and specific immunotherapy with
birch pollen. Mol Nutr Food Res 2004;48:441-8. Ib
179. Tankersley MS, Butler KK, Butler WK, Goetz DW. Local reactions
during allergen immunotherapy do not require dose adjustment. J Allergy
Clin Immunol 2000;106:840-3. III
180. Kelso JM. The rate of systemic reactions to immunotherapy injections is
the same whether or not the dose is reduced after a local reaction. Ann
Allergy Asthma Immunol 2004;92:225-7. III
181. Roy SR, Sigmon JR, Olivier J, Moffitt JE, Brown DA, Marshall GD.
Increased frequency of large local reactions in patients who experience
systemic reactions on allergen immunotherapy. Ann Allergy Asthma
Immunol 2007;99:82-6. III
182. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC. Systemic
reactions and fatalities associated with allergen immunotherapy.
Ann Allergy Asthma Immunol 2001;87(suppl 1):47-55. III
183. Malling HJ. Minimising the risks of allergen-specific injection immunotherapy.
Drug Saf 2000;23:323-32.
184. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to
allergen immunotherapy injections. J Allergy Clin Immunol 2006;117:
169-75. III
185. Ragusa FV, Passalacqua G, Gambardella R, et al. Nonfatal systemic reactions
to subcutaneous immunotherapy: a 10-year experience. J Investig
Allergol Clin Immunol 1997;7:151-4. III
186. Ragusa VF, Massolo A. Non-fatal systemic reactions to subcutaneous
immunotherapy: a 20-year experience comparison of two 10-year periods.
Allerg Immunol (Paris) 2004;36:52-5. III
187. Moreno C, Cuesta-Herranz J, Fernandez-Tavora L, Alvarez-Cuesta E.
Immunotherapy safety: a prospective multi-centric monitoring study
of biologically standardized therapeutic vaccines for allergic diseases.
Clin Exp Allergy 2004;34:527-31. III
188. Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of
fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy
Clin Immunol 2004;113:1129-36. III
189. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from
immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol
1987;79:660-77. III
190. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities
from skin testing and immunotherapy 1985-1989. J Allergy Clin
Immunol 1993;92:6-15. III
191. Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. Immunotherapy
with a standardized Dermatophagoides pteronyssinus extract.
Systemic reactions during the rush protocol in patients suffering from
asthma. J Allergy Clin Immunol 1989;83:797-802. IIa
192. Greenberg MA, Kaufman CR, Gonzalez GE, Rosenblatt CD, Smith LJ,
Summers RJ. Late and immediate systemic-allergic reactions to inhalant
allergen immunotherapy. J Allergy Clin Immunol 1986;77:865-70.
193. Matloff SM, Bailit IW, Parks P, Madden N, Greineder DK. Systemic
reactions to immunotherapy. Allergy Proc 1993;14:347-50. IV
194. Subcutaneous immunotherapy. Allergy 2006;61(suppl 82):5-13.
195. Javeed N, Javeed H, Javeed S, Moussa G, Wong P, Rezai F. Refractory
anaphylactoid shock potentiated by beta-blockers. Catheter Cardiovasc
Diagn 1996;39:383-4.
196. Kivity S, Yarchovsky J. Relapsing anaphylaxis to bee sting in a patient
treated with beta-blocker and Ca blocker. J Allergy Clin Immunol 1990;
85:669-70. IV
197. Lang DM, Alpern MB, Visintainer PF, Smith ST. Elevated risk of anaphylactoid
reaction from radiographic contrast media is associated
with both beta-blocker exposure and cardiovascular disorders. Arch Intern
Med 1993;153:2033-40. III
198. Lang DM, Alpern MB, Visintainer PF, Smith ST. Increased risk for anaphylactoid
reaction from contrast media in patients on beta-adrenergic
blockers or with asthma. Ann Intern Med 1991;115:270-6. III
199. Bickell WH, Dice WH. Military antishock trousers in a patient with
adrenergic-resistant anaphylaxis. Ann Emerg Med 1984;13:189-90. IV
200. Jacobs RL, Rake GW Jr, Fournier DC, Chilton RJ, Culver WG, Beckmann
CH. Potentiated anaphylaxis in patients with drug-induced betaadrenergic
blockade. J Allergy Clin Immunol 1981;68:125-7. IV
201. Newman BR, Schultz LK. Epinephrine-resistant anaphylaxis in a patient
taking propranolol hydrochloride. Ann Allergy 1981;47:35-7. IV
202. Toogood JH. Risk of anaphylaxis in patients receiving beta-blocker
drugs. J Allergy Clin Immunol 1988;81:1-5. IV
203. Hepner MJ, Ownby DR, Anderson JA, Rowe MS, Sears-Ewald D,
Brown EB. Risk of systemic reactions in patients taking beta-blocker
drugs receiving allergen immunotherapy injections. J Allergy Clin Immunol
1990;86:407-11. III
204. Muller UR, Haeberli G. Use of beta-blockers during immunotherapy for
Hymenoptera venom allergy. J Allergy Clin Immunol 2005;115:
606-10. III
205. Sherman MS, Lazar EJ, Eichacker P. A bronchodilator action of glucagon.
J Allergy Clin Immunol 1988;81:908-11. IV
206. Thomas M, Crawford I. Best evidence topic report. Glucagon infusion
in refractory anaphylactic shock in patients on beta-blockers. Emerg
Med J 2005;22:272-3. IV
207. Pumphrey RS. Lessons for management of anaphylaxis from a study of
fatal reactions. Clin Exp Allergy 2000;30:1144-50. III
208. Simons FE, Chan ES, Gu X, Simons KJ. Epinephrine for the out-of-hospital
(first-aid) treatment of anaphylaxis in infants: is the ampule/syringe/
needle method practical? J Allergy Clin Immunol 2001;108:1040-4. IIa
209. Simons FE, Gu X, Johnston LM, Simons KJ. Can epinephrine inhalations
be substituted for epinephrine injection in children at risk for systemic
anaphylaxis? Pediatrics 2000;106:1040-4. Ib
210. Simons FE, Gu X, Silver NA, Simons KJ. EpiPen Jr versus EpiPen in
young children weighing 15 to 30 kg at risk for anaphylaxis. J Allergy
Clin Immunol 2002;109:171-5. Ib
211. Simons FE, Gu X, Simons KJ. Outdated EpiPen and EpiPen Jr autoinjectors:
past their prime? J Allergy Clin Immunol 2000;105:1025-30. Ib
212. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular
versus subcutaneous injection. J Allergy Clin Immunol 2001;
108:871-3. Ib
213. Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in
children with a history of anaphylaxis. J Allergy Clin Immunol 1998;
101:33-7. Ib
214. Bernstein JA. Pharmacoeconomic considerations for allergen immunotherapy.
Clin Allergy Immunol 2004;18:151-64. III
215. Practice parameters for the diagnosis and treatment of asthma. Joint
Task Force on Practice Parameters, representing the American Academy
of Allergy Asthma and Immunology, the American College of
Allergy, Asthma and Immunology, and the Joint Council of Allergy,